Biomx Inc's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Biomx Inc in the second quarter 2026?
Biomx Inc recorded a cumulative net loss of $-35 million during 12 months ending in the second quarter 2026, resulting in a negative return on equity (ROE) of -533.84%.

Within the Biotechnology & Pharmaceuticals industry 106 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 3768 to 3782.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Equity Change	-8.02 %	-	-	-72.33 %	-
Y / Y Net Income Change	-	149.9 %	-	-	-
Net Income (TTM) in Millions	-35	-25	-36	37	19
Return On Equity (TTM)	-533.84 %	-360.02 %	-274.01 %	190.95 %	70.26 %
PHGE's Total Ranking	# 3782	# 3768	# 30	# 83	#
Equity (TTM) in Millions	18	-1	-1	10	19
Seq. Equity Change	-	-	-	-45.27 %	-21.79 %
Seq. Net Income Change	-	-	-	51.83 %	-21.18 %

Back to PHGE Management Effectiveness >> PHGE's 5 Years Annual ROE >> Compare PHGE ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 107
Sector	# 737
Overall	# 3782

Return On Equity Statistics
High	Average	Low
496.46 %	49.1 %	-533.84 %
(Mar 31 2024)		(Jun 30 2026)

PHGE Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	-1	24	3	21	48
Y / Y Equity Change	-	683.77 %	-85.36 %	-55.74 %	-17.29 %
Net Income in Millions	-36	18	-26	28	36
Y / Y Net Income Change	-	-	-	-21.83 %	20.41 %
Return On Equity	-	73.41 %	-849.37 %	134.59 %	76.21 %

Back to PHGE Management Effectiveness >> PHGE's 5 Years Annual ROE >> Compare PHGE ROE to its Competitors

Annual Roe Comment

Despite deterioration in net income, company improved ROE to in 2025, company improved ROE to 76.21 % compared to the prior year.

More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
PHGE's' Return on Equity at Yahoo Finance
PHGE's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for PHGE's Competitors
Subscribers only: Roe for Biomx Inc's Suppliers
Subscribers only: Return On Equity for PHGE's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector

ROE

Date modified: 2026-09-26T07:35:44+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.